» Articles » PMID: 33004381

A Systematic Review of Patient-reported Outcome Measures (PROMs) in Cystic Fibrosis

Overview
Journal BMJ Open
Specialty General Medicine
Date 2020 Oct 2
PMID 33004381
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Background: To determine patient-reported outcome measures (PROMs) which may be suitable for incorporation into the Australian Cystic Fibrosis Data Registry (ACFDR) by identifying PROMs administered in adult and paediatric cystic fibrosis (CF) populations in the last decade.

Methods: We searched MEDLINE, EMBASE, Scopus, CINAHL, PsycINFO and Cochrane Library databases for studies published between January 2009 and February 2019 describing the use of PROMs to measure health-related quality of life (HRQoL) in adult and paediatric patients with CF. Validation studies, observational studies and qualitative studies were included. The search was conducted on 13 February 2019. The COnsensus-based Standards for the selection of health Measurement INstruments Risk of Bias Checklist was used to assess the methodological quality of included studies.

Results: Twenty-seven different PROMs were identified. The most commonly used PROMs were designed specifically for CF. Equal numbers of studies were conducted on adult (32%, n=31), paediatric (35%, n=34) and both (27%, n=26) populations. No PROMs were used within a clinical registry setting previously. The two most widely used PROMs, the Cystic Fibrosis Questionnaire-Revised (CFQ-R) and the Cystic Fibrosis Quality of Life Questionnaire (CFQoL), demonstrated good psychometric properties and acceptability in English-speaking populations.

Discussion: We found that although PROMs are widely used in CF, there is a lack of reporting on the efficacy of methods and timepoints of administration. We identified the CFQ-R and CFQoL as the most suitable for incorporation in the ACFDR as they captured significant effects of CF on HRQoL and were reliable and valid in CF populations. These PROMs will be used in a further qualitative study assessing patients' with CF and clinicians' perspectives toward the acceptability and feasibility of incorporating a PROM in the ACFDR.

Prospero Registration Number: CRD42019126931.

Citing Articles

Tools used to measure quality of life in adults with cystic fibrosis- a systematic review.

Snop-Perkowska D, Switalski J, Wnuk K, Olszewski P, Augustynowicz A Health Qual Life Outcomes. 2025; 23(1):10.

PMID: 39901267 PMC: 11792344. DOI: 10.1186/s12955-025-02338-2.


Development and validation of a novel personalized electronic patient-reported outcome measure to assess quality of life (Q-LIFE): a prospective observational study in people with Cystic Fibrosis.

Muilwijk D, van Paridon T, van der Heijden D, Faber-Bisschop B, Zomer-van Ommen D, Heijerman H EClinicalMedicine. 2023; 62:102116.

PMID: 37554124 PMC: 10404867. DOI: 10.1016/j.eclinm.2023.102116.


Health-Related Quality of Life in Adults with Cystic Fibrosis: Familial, Occupational, Social, and Mental Health Predictors.

Ancel J, Launois C, Perotin J, Ravoninjatovo B, Mulette P, Hagenburg J Healthcare (Basel). 2022; 10(7).

PMID: 35885877 PMC: 9325027. DOI: 10.3390/healthcare10071351.


Implementing PROMS for elective surgery patients: feasibility, response rate, degree of recovery and patient acceptability.

Brusco N, Atkinson V, Woods J, Myles P, Hodge A, Jones C J Patient Rep Outcomes. 2022; 6(1):73.

PMID: 35798915 PMC: 9263014. DOI: 10.1186/s41687-022-00483-6.


Elexacaftor-Tezacaftor-Ivacaftor as a Final Frontier in the Treatment of Cystic Fibrosis: Definition of the Clinical and Microbiological Implications in a Case-Control Study.

Migliorisi G, Collura M, Ficili F, Pensabene T, Bongiorno D, Collura A Pharmaceuticals (Basel). 2022; 15(5).

PMID: 35631432 PMC: 9145356. DOI: 10.3390/ph15050606.


References
1.
Modi A, Lim C, Driscoll K, Piazza-Waggoner C, Quittner A, Wooldridge J . Changes in pediatric health-related quality of life in cystic fibrosis after IV antibiotic treatment for pulmonary exacerbations. J Clin Psychol Med Settings. 2010; 17(1):49-55. PMC: 2847844. DOI: 10.1007/s10880-009-9179-2. View

2.
Bell S, Bye P, Cooper P, Martin A, McKay K, Robinson P . Cystic fibrosis in Australia, 2009: results from a data registry. Med J Aust. 2011; 195(7):396-400. DOI: 10.5694/mja11.10719. View

3.
Driscoll K, Modi A, Filigno S, Brannon E, Chamberlin L, Stark L . Quality of life in children with CF: Psychometrics and relations with stress and mealtime behaviors. Pediatr Pulmonol. 2015; 50(6):560-7. PMC: 4431901. DOI: 10.1002/ppul.23149. View

4.
Abbott J, Hart A, Morton A, Dey P, Conway S, Webb A . Can health-related quality of life predict survival in adults with cystic fibrosis?. Am J Respir Crit Care Med. 2008; 179(1):54-8. DOI: 10.1164/rccm.200802-220OC. View

5.
Tibosch M, Sintnicolaas C, Peters J, Merkus P, Yntema J, Verhaak C . How about your peers? Cystic fibrosis questionnaire data from healthy children and adolescents. BMC Pediatr. 2011; 11:86. PMC: 3198681. DOI: 10.1186/1471-2431-11-86. View